Senti Biosciences Holdings, Inc. 8-K

What Happened Senti Biosciences Holdings, Inc. (SNTI) reported that its subsidiary Senti Holdings, Inc. issued and sold $10.0 million in aggregate principal of Senior Secured Convertible Notes to Celadon Partners SPV 24 on May 20, 2026, under a Securities Purchase Agreement dated April 27, 2026. The filing (Form 8‑K) also discloses that, under certain conditions, the company may pursue a transaction in which an entity affiliated with Celadon would merge into Senti Holdings and Senti Holdings would issue a contingent value right to Senti Biosciences stockholders that could pay up to $60.0 million in cash if regulatory and sales milestones for the product candidate SENTI‑202 are met. The company says it will file proxy materials (Schedule 14A) and mail definitive proxy statements to stockholders if and when required.

Key Details

• Issuance date and amount: $10.0 million of Senior Secured Convertible Notes issued May 20, 2026 to Celadon Partners SPV 24.
• Agreement: Sale pursuant to the Securities Purchase Agreement dated April 27, 2026.
• Potential contingent payout: A proposed contingent value right tied to SENTI‑202 could pay up to $60.0 million in cash, subject to regulatory and sales milestones.
• Next steps: The company intends to file a preliminary and then definitive proxy statement with the SEC if Notes beyond the Exchange Cap are issued or the related Celadon transaction is pursued; stockholder vote and proxy materials will follow.

Why It Matters This financing provides Senti immediate capital ($10M) but also creates a new secured convertible debt obligation that could affect the company’s capital structure and potentially dilute shareholders if converted. The disclosed possible Celadon-related merger and contingent value right would require additional SEC filings and a stockholder vote, and could result in up to $60M of milestone-based cash payments tied to SENTI‑202. Investors should watch forthcoming proxy materials and filings for full terms, conversion mechanics, dilution effects, and milestone definitions before making decisions.